000			01871 a2200517 4500
005			20250514072218.0
264		0	_c20040304
008			200403s 0 0 eng d
022			_a0105-4538
024	7		_a10.1034/j.1398-9995.2003.00083.x _2doi
040			_aNLM _beng _cNLM
100	1		_aJahnz-Rózyk, K
245	0	0	_aCc-chemokine eotaxin as a marker of efficacy of specific immunotherapy in patients with intermittent IgE-mediated allergic rhinoconjunctivitis. _h[electronic resource]
260			_bAllergy _cJul 2003
300			_a595-601 p. _bdigital
500			_aPublication Type: Comparative Study; Evaluation Study; Journal Article
650	0	4	_aAdministration, Inhalation
650	0	4	_aAdult
650	0	4	_aAllergens _xadverse effects
650	0	4	_aAnti-Allergic Agents _xtherapeutic use
650	0	4	_aBetula _xadverse effects
650	0	4	_aBiomarkers _xblood
650	0	4	_aChemokines, CC _xblood
650	0	4	_aConjunctivitis, Allergic _xblood
650	0	4	_aDesensitization, Immunologic
650	0	4	_aDrug Therapy, Combination
650	0	4	_aEdible Grain _xadverse effects
650	0	4	_aFemale
650	0	4	_aHistamine H1 Antagonists, Non-Sedating _xtherapeutic use
650	0	4	_aHumans
650	0	4	_aHypersensitivity, Immediate _xblood
650	0	4	_aImmunoglobulin E _xblood
650	0	4	_aLoratadine _xtherapeutic use
650	0	4	_aMale
650	0	4	_aPoaceae _xadverse effects
650	0	4	_aPoland _xepidemiology
650	0	4	_aPollen _xadverse effects
650	0	4	_aRhinitis, Allergic, Seasonal _xblood
650	0	4	_aStatistics as Topic
650	0	4	_aTreatment Outcome
700	1		_aTargowski, T
700	1		_aGłodzinska-Wyszogrodzka, E
700	1		_aPłusa, T
773	0		_tAllergy _gvol. 58 _gno. 7 _gp. 595-601
856	4	0	_uhttps://doi.org/10.1034/j.1398-9995.2003.00083.x _zAvailable from publisher's website
999			_c12606293 _d12606293